原研港

原研港 (also known as 原研药港) is a Chinese clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative small molecule therapeutics. The company targets a variety of therapeutic areas, including cardiovascular diseases, urogenital disorders, respiratory conditions, and central nervous system diseases. Its clinical pipeline features MT-1207, a multi-target alpha-1 adrenergic and 5-HT2A receptor antagonist in Phase 2 development for hypertension and benign prostatic hyperplasia, and PE-001, a novel small molecule that has completed Phase 2 trials for premature ejaculation. Additionally, the company is advancing PH-501 into Phase 1b/2 trials for pulmonary arterial hypertension and developing early-stage candidates like CA-301 for brain science indications. With integrated capabilities spanning from early R&D to GMP manufacturing across facilities in Shanghai, Shenyang, and Beijing, 原研港 aims to deliver first-in-class and best-in-class original drugs to address significant unmet medical needs.